Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
4001
DELISTED
Blueprint Medicines
BPMC
| $1.38M | ﹤0.01% |
+18,258
| New | +$1.28M |
|
|
WFT
4002
CALL
DELISTED
Weatherford International plc
WFT
| $1.38M | ﹤0.01% |
330,200
-32,100
| -9% | -$118K |
|
|
ZOES
4003
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $1.38M | ﹤0.01% |
82,281
-191,225
| -70% | -$2.68M |
|
|
KEM
4004
PUT
DELISTED
KEMET Corporation
KEM
| $1.38M | ﹤0.01% |
91,300
+44,600
| +96% | +$849K |
|
4005
CALL
ProShares UltraShort Euro
EUO
$33.1M
| $1.37M | ﹤0.01% |
64,800
-5,700
| -8% | -$125K |
|
4006
Ford
F
$57.3B
| $1.37M | ﹤0.01% |
109,991
-550,925
| -83% | -$6.78M |
|
4007
Columbus McKinnon
CMCO
$556M
| $1.37M | ﹤0.01% |
34,327
+16,679
| +95% | +$639K |
|
4008
PUT
KRONOS Worldwide
KRO
$975M
| $1.37M | ﹤0.01% |
53,200
+43,900
| +472% | +$1.15M |
|
|
SGEN
4009
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.37M | ﹤0.01% |
25,600
+1,300
| +5% | +$75.9K |
|
4010
Invesco Dorsey Wright SmallCap Momentum ETF
DWAS
$455M
| $1.37M | ﹤0.01% |
+28,176
| New | +$1.35M |
|
4011
CALL
Leidos
LDOS
$18B
| $1.37M | ﹤0.01% |
21,200
+8,200
| +63% | +$514K |
|
4012
PUT
ScottsMiracle-Gro
SMG
$3.55B
| $1.37M | ﹤0.01% |
12,800
+8,000
| +167% | +$799K |
|
4013
Suburban Propane Partners
SPH
$1.18B
| $1.37M | ﹤0.01% |
+56,512
| New | +$1.41M |
|
4014
UMB Financial
UMBF
$11.5B
| $1.37M | ﹤0.01% |
+19,032
| New | +$1.4M |
|
4015
PUT
Vornado Realty Trust
VNO
$7.28B
| $1.37M | ﹤0.01% |
17,500
-3,900
| -18% | -$298K |
|
|
ARRY
4016
CALL
DELISTED
Array Biopharma Inc
ARRY
| $1.37M | ﹤0.01% |
106,900
-6,400
| -6% | -$72.8K |
|
|
TCO
4017
CALL
DELISTED
Taubman Centers Inc.
TCO
| $1.37M | ﹤0.01% |
20,900
+13,400
| +179% | +$736K |
|
|
LNCE
4018
PUT
DELISTED
Snyders-Lance, Inc.
LNCE
| $1.37M | ﹤0.01% |
27,300
+22,000
| +415% | +$873K |
|
|
ARRY
4019
PUT
DELISTED
Array Biopharma Inc
ARRY
| $1.37M | ﹤0.01% |
106,700
-25,200
| -19% | -$287K |
|
4020
Atlantic Union Bankshares
AUB
$6.12B
| $1.36M | ﹤0.01% |
37,737
-41,691
| -52% | -$1.49M |
|
4021
CALL
IAMGOLD
IAG
$10.4B
| $1.36M | ﹤0.01% |
234,100
+31,000
| +15% | +$177K |
|
4022
PUT
Terex
TEX
$7.76B
| $1.36M | ﹤0.01% |
28,300
+2,300
| +9% | +$106K |
|
4023
CALL
CBRE Group
CBRE
$44.3B
| $1.36M | ﹤0.01% |
31,500
+11,700
| +59% | +$485K |
|
|
BIVV
4024
CALL
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $1.36M | ﹤0.01% |
25,300
+9,300
| +58% | +$509K |
|
|
FIT
4025
CALL
DELISTED
Fitbit, Inc. Class A common stock
FIT
| $1.36M | ﹤0.01% |
238,700
-268,900
| -53% | -$1.71M |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.